Your browser doesn't support javascript.
loading
Comprehensive analysis of T cell exhaustion related signature for predicting prognosis and immunotherapy response in HNSCC.
Zhang, Wei; Qu, Mei; Yin, Chun; Jin, Zhiliang; Hu, Ya.
Afiliación
  • Zhang W; Department of Oncology, Jingzhou Hospital, Yangtze University, Jingzhou, China.
  • Qu M; Department of Oncology, Jingzhou Hospital, Yangtze University, Jingzhou, China.
  • Yin C; Department of Oncology, Jingzhou Hospital, Yangtze University, Jingzhou, China.
  • Jin Z; Department of Oncology, Jingzhou Hospital, Yangtze University, Jingzhou, China.
  • Hu Y; Department of Pharmacology, Health Science Center, Yangtze University, 1 Nanhuan Road, Jingzhou, 434023, Hubei, China. yahu@yangtzeu.edu.cn.
Discov Oncol ; 15(1): 56, 2024 Mar 02.
Article en En | MEDLINE | ID: mdl-38430429
ABSTRACT

BACKGROUND:

T cell exhaustion (TEX) signifies a condition of T cell disorder which implicate the therapeutic benefits and prognostic significance in patients with cancer. However, its role in the Head and Neck Squamous Carcinoma (HNSCC) remains incompletely understood.

METHODS:

The detailed data of HNSCC samples were obtained from The Cancer Genome Atlas (TCGA) database and two Gene Expression Omnibus (GEO) datasets. We computed the expression scores of four TEX-related pathways and detected gene modules closely linked to these pathways, indicating prognostic significance. Following this, regression analyses were performed to select eight genes for the development of a predictive signature. The predictive capacity of this signature was evaluated. Additionally, we examined the relationships between TEX-related signature risk scores and the effectiveness of immunotherapy as well as drug sensitivity.

RESULTS:

A novel prognostic model, comprising eight TEX-related genes, was established for patients with HNSCC. The prognostic value was further confirmed using additional GEO datasets GSE65858 and GSE27020. This signature enables the stratification of patients into high- and low- risk groups, each showing distinct survival outcomes and responsiveness to immunotherapy. The low-risk group demonstrated improved prognosis and enhanced efficacy of immunotherapy. In addition, AZD6482, TAF1, Ribociclib, LGK974, PF4708671 and other drugs showed increased sensitivity in the high-risk group based on drug sensitivity values, offering tailored therapeutic recommendations for individuals with various risks profiles.

CONCLUSION:

In conclusion, we developed a novel T cell exhaustion-associated signature, which holds considerable predictive value for both the prognosis of patients with HNSCC and the effectiveness of tumor immunotherapy.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Discov Oncol Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Discov Oncol Año: 2024 Tipo del documento: Article